

[My Account](#) [Subscribe Now](#) [Authors](#) [About Us](#) [Podcasts](#)

Editor's Choice

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.

[Read this Article](#)

From female warriors in the rainforest to infectious disease specialists: in advance of International Day of the World's Indigenous Peoples, Aug 9, Izabella Safe discusses COVID-19 in the Amazon.

[Read this Essay](#)

EDITORIAL

Fighting for air: racial inequity in respiratory health

COMMENT

E-cigarettes for smoking reduction: a piece of the public health puzzle

COVID-19 and ECMO: a call for close cooperation and more investigation

RAS inhibition and COVID-19: more questions than answers?

A leap forward in assessing host-directed therapies for tuberculosis

Exploiting an early immunological window of opportunity in COVID-19

Recovery after prolonged ICU treatment in patients with COVID-19

Addressing a system failure to diagnose COPD and asthma

Misconceptions regarding symptoms of sarcoidosis

COVID-19 vaccination in patients with α 1-antitrypsin deficiency

Ongoing asthma management in children during the COVID-19 pandemic: to step down or not to step down?



CORRESPONDENCE

Cytokine adsorption and ECMO in patients with COVID-19

Cytokine adsorption and ECMO in patients with COVID-19

Cytokine adsorption and ECMO in patients with COVID-19 – Author's reply

Association between sex and SARS-CoV-2 infection and hospitalisation as a result of COVID-19

Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?

Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19

Extracorporeal membrane oxygenation for COVID-19 during first and second waves

COVID-19 hospital admissions: Brazil's first and second waves compared



CORRECTIONS

Correction to *Lancet Respir Med* 2021; published online June 17, [https://doi.org/10.1016/S2213-2600\(21\)00237-X](https://doi.org/10.1016/S2213-2600(21)00237-X)

NEWS

Lifting of COVID-19 restrictions in the UK and the Delta variant

WHO's Tobacco Taxation Manual 2.0

SPOTLIGHT

I won't let cystic fibrosis stop me from living my best life

Research priorities for exacerbations of COPD

Artificial intelligence hold promise in the ICU

ARTICLES

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with *EGFR*T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial

Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study

The sputum microbiome and clinical outcomes in patients with

Online First

August 2, 2021

Time to move away from an oxygen-centric model of pulmonary infarction?

August 2, 2021

Time to move away from an oxygen-centric model of pulmonary infarction? – Authors' reply

July 29, 2021

Tobacco industry capitalises on the COVID-19 pandemic

July 28, 2021

Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities

July 28, 2021

PRINCIPLE: a community-based COVID-19 platform trial

July 27, 2021

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

July 23, 2021

Advancing precision medicine for acute

directed
label,
Open

syndrome

**View the full list of
Online First articles**

Adjunctive host-therapies for pulmonary tuberculosis: a prospective, open-phase 2, randomised controlled trial

Access

Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study

Open Access

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Open Access

VIEWPOINT

The Berlin definition of acute respiratory distress syndrome: should patients receiving high-flow nasal oxygen be included?

You are receiving this email because you subscribed to TheLancet.com alerting service.

This email has been sent from The Lancet Respiratory Medicine, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084.

Update mailing preferences to choose which Lancet journals you receive alerts from. [Follow this link to unsubscribe.](#)

[Privacy Policy](#)

Copyright © 2021 Elsevier Limited except certain content provided by third parties. The Lancet is a trade mark of Elsevier Limited.

Subscription ID: 7fee2401-54e6-4917-95b1-08897c324d24 Webuser ID: 30316685 Results Event ID: c9ccc06b-8159-4e06-927c-e620069a7895